Therapy Areas: Cardiovascular
Staten partners with Novo Nordisk to dose SST-5058 in first healthy volunteer for treatment of dyslipidaemia
21 July 2020 -

Biotechnology company Staten Biotechnology BV announced on Tuesday that it has started the dosing of its lead STT-5058 drug candidate in a first-in-human clinical study for the novel treatment for dyslipidaemia under a prior collaboration with Novo Nordisk.

The company added that STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk for the treatment of dyslipidaemia. This "recycling" antibody with extended half-life has the potential to lower triglyceride levels and increase clearance of ApoC3-containing atherogenic particles.

Under the terms of the agreement, Novo Nordisk is providing funding and support to Staten for the development of STT-5058 in this indication.The partners will able to rapidly progress from research to product manufacturing to a clinical trial for the lead drug candidate.

Multiple studies have identified ApoC3 levels to be inversely associated with a favourable lipid profile and insulin resistance, both key components in managing residual cardiovascular risk. Dyslipidemia is an abnormal amount of lipids triglycerides, cholesterol and/or fat phospholipids) in the blood, concluded the company.

Login
Username:

Password: